Identification and mechanisms of endocrine resistance.

作者信息

Miller William R

机构信息

University of Edinburgh, Western General Hospital, Edinburgh, UK.

出版信息

Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S19. doi: 10.1186/bcr2179. Epub 2008 Dec 18.

DOI:10.1186/bcr2179

PMID:19128432

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2614845/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1fb/2614845/5dc37b63662f/bcr2179-1.jpg

相似文献

Identification and mechanisms of endocrine resistance.

Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S19. doi: 10.1186/bcr2179. Epub 2008 Dec 18.

Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.

Oncotarget. 2015 Apr 20;6(11):8648-62. doi: 10.18632/oncotarget.3257.

Endocrine resistance in breast cancer: what really matters?

Ann Oncol. 2007 Aug;18(8):1289-91. doi: 10.1093/annonc/mdm359.

p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.

Breast Cancer Res. 2006;8(4):R48. doi: 10.1186/bcr1536.

Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.

Maturitas. 2006 Jul 20;54(4):342-51. doi: 10.1016/j.maturitas.2006.06.003. Epub 2006 Jul 5.

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.

Clin Cancer Res. 2007 Apr 1;13(7):1950-4. doi: 10.1158/1078-0432.CCR-06-2540.

Endocrine therapy for the treatment of postmenopausal women with breast cancer.

Expert Rev Anticancer Ther. 2009 Feb;9(2):187-98. doi: 10.1586/14737140.9.2.187.

Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.

Clin Cancer Res. 2006 Aug 15;12(16):4790-3. doi: 10.1158/1078-0432.CCR-06-1535.

Intratumoural inflammation and endocrine resistance in breast cancer.

Endocr Relat Cancer. 2015 Feb;22(1):R51-67. doi: 10.1530/ERC-14-0096. Epub 2014 Nov 17.

Cancer Navigation Strategy for Endocrine Therapy-Resistant Breast Tumors.

Trends Cancer. 2018 Jun;4(6):404-407. doi: 10.1016/j.trecan.2018.04.005. Epub 2018 May 19.

引用本文的文献

Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer.

Clin Cancer Res. 2021 May 1;27(9):2648-2662. doi: 10.1158/1078-0432.CCR-20-2961. Epub 2021 Feb 4.

Transcriptional regulation prediction of antiestrogen resistance in breast cancer based on RNA polymerase II binding data.

BMC Bioinformatics. 2014;15 Suppl 2(Suppl 2):S10. doi: 10.1186/1471-2105-15-S2-S10. Epub 2014 Jan 24.

Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to'?

Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S15. doi: 10.1186/bcr2175. Epub 2008 Dec 18.

本文引用的文献

Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer.

Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S17. doi: 10.1186/bcr2177. Epub 2008 Dec 18.

Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors.

Cancer. 2008 Feb 1;112(3 Suppl):689-694. doi: 10.1002/cncr.23187.

Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.

Pharmacogenet Genomics. 2007 Oct;17(10):813-26. doi: 10.1097/FPC.0b013e32820b853a.

Aromatase inhibitors--gene discovery.

J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):130-42. doi: 10.1016/j.jsbmb.2007.05.013. Epub 2007 May 29.

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

J Clin Oncol. 2006 Jul 1;24(19):3019-25. doi: 10.1200/JCO.2005.04.3034. Epub 2006 Jun 5.

Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S119-23. doi: 10.1677/erc.1.00995.

Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S113-7. doi: 10.1677/erc.1.01044.

Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):91-5. doi: 10.1016/j.jsbmb.2005.04.017.

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):951s-8s.

Estrogen and progesterone receptor isoforms: clinical significance in breast cancer.

Breast Cancer Res Treat. 2004;87 Suppl 1:S3-10. doi: 10.1007/s10549-004-1577-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验